Emgrast M 250Mcg Injection

Emgrast M 250Mcg Injection is an immunostimulator, a GM-CSF (recombinant granulocyte macrophage colony stimulating factor) that is prescribed to cancer patients for fighting infections. It is helps accelerate the recovery of white blood cells after chemotherapy and is prescribed to patients after chemotherapy in Acute Myelogenous Leukemia (AML), bone marrow transplantation, and peripheral blood stem cell transplantation.

Consult your doctor regarding the right dosage. Dosage depends upon the condition or cancer being treated, your age, height and several other factors. Emgrast M 250Mcg Injection is used as a subcutaneous injection or can also be given intravenously. Avoid its usage if you are planning to become pregnant. Tell your doctor if you are using any other drugs.

Some common side effects of Emgrast M 250Mcg Injection include nausea, vomiting, diarrhea, weakness, stomach pain, mouth sores, hair loss, bone, joint, or muscle pain. Allergic reaction to this medication can cause itching, rash, hives. Seek immediate medical attention in case these side effects don't go fast or if you notice any serious side effects like sweating, nosebleeds, fainting, chest pain, difficulty breathing, unusual bruising or bleeding, fever or swelling around the eyes, stomach, feet, ankles, or lower legs.

Do not take Emgrast M 250Mcg Injection if you have leukemic myeloid blasts in the bone marrow, are pregnant, breastfeeding or have known allergies to any of the ingredients of this medicine.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Internal Medicine Specialist before using this medicine.

• Bone Pain

• Decreased Blood Pressure

• Fever

• Breathlessness

• Feeling Of Discomfort

• Vomiting

• Flushing

• Nausea

• Flu-Like Symptoms

• Rash

• Diarrhoea

• Shortness Of Breath

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Internal Medicine Specialist before using this medicine.

• Is It safe with alcohol?

  Interaction with alcohol is unknown. Please consult your doctor.

• Are there any pregnancy warnings?

  Emgrast m 500mcg injection may be unsafe to use during pregnancy.
  Animal studies have shown adverse effects on the foetus, however, there are limited human studies. The benefits from use in pregnant women may be acceptable despite the risk. Please consult your doctor.

• Are there any breast-feeding warnings?

  Unknown. Human and animal studies are not available. Please consult your doctor.

• Is it safe to drive while on this medicine?

  There is no data available. Please consult doctor before consuming the drug.

• Does this affect kidney function?

  There is no interaction between renal impairment and consuming this drug. So dose alteration is not needed.

• Does this affect liver function?

  There is no data available. Please consult doctor before consuming the drug.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Internal Medicine Specialist before using this medicine.

• Are there any missed dose instructions?

  If you miss a dose of Sargramostim, please consult your doctor.

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Internal Medicine Specialist before using this medicine.

Emgrast M 250Mcg Injection is a white blood cells rejuvenating drug given after chemotherapy. This drug triggers a JAK2 STAT1/STAT3 signal transduction pathway by attaching to the Granulocyte-macrophage colony (GM-CSF-R-alpha or CSF2R).

Information given here is based on the salt content of the medicine. Uses and effects of the medicine may vary from person to person. It is advisable to consult a Internal Medicine Specialist before using this medicine.